Clinical Efficacy Of Kangfuxin Liquid Combined With Rabeprazole Triple Therapy In The Treatment Of Peptic Ulcer And Its Effect On The Expression Of NO And IL-17

Objective:To analyze the clinical effect of kangfux:in Liquid combined with rabeprazole triple therapy on patients with peptic ulcer,with the focus on the detection of the effect of this therapy on NO and IL-17 in patients with peptic ulcer.Methods:120 cases of peptic ulcer patients admitted and treated in the department of gastroenterology of our hospital from August 2016 to August 2018 were randomly made into balls according to the number at the time of admission,placed in boxes,and then removed at intervals and put into the observation group and the control group to divide the groups.There were 60 cases in each group.All patients were diagnosed with peptic ulcer by gastroscopy and rapid urease test.There was no statistically significant difference in general data between the two groups(P>0.05),which was comparable.The content of treatment,treatment time,expected results and other major treatment programs of all patients should be approved by the ethics committee of the hospital before use,and carefully communicate with the patients and their families,and all patients should sign the informed consent form.Patients in the control group were treated with rabeprazole trigeminal therapy(rabeprazole,clarithromycin and amoxicillin),in which clarithromycin was 0.5g each time,twice a day,rabeprazole was 10mg/time,twice a day,amoxicillin was 0.5g/time,and twice a day.Treatment of 30 d;On the basis of the same method as the control group,the observation group was treated with the control group method.On this basis,kangfuxin Liquid was added for 30d.The clinical efficacy and the levels of NO and IL-17 before and after treatment,SPSS19.0 software was used for data processing,x2 test was used for comparison of counting data rate,and t test was used for comparison between measurement data groups.When P<0.05,the difference was considered statistically significant.Results:The comparison of clinical efficacy between the two groups is shown in table 2-1.On the fifth day of treatment,there was no significant difference in the total effective rate between the observation group and the control group(P>0.05).On the 15th day of treatment,there was no significant difference in the total effective rate between the observation group and the control group(P>0.05).At the 30th day of treatment,the total effective rate in the observation group was 96.49%,and the total effective rate in the control group was 84.21%,with a significant difference(chi-square=4.93,P<0.05).Comparisons of symptom scores between the two groups:After treatment,abdominal pain,acid reflux and belching in the two groups were significantly improved compared with those before treatment,and the total score of symptoms showed a downward trend.On the fifth and fifteenth day,compared with the control group,the abdominal pain,acid reflux and belching did not improve significantly,the total score of symptoms did not decrease significantly(P>0.05).On the thirtieth day of treatment,the total score of symptoms in the observation group was significantly improved,and the total score of symptoms in the treatment group was significantly lower than that in the control group(t=-3.48,-3.65,-2.50,P<0.05).The difference was significant(t=-3.48,-3.65,P<0.05),the improvement of abdominal pain was not significant(P>0.05).After treatment,the expression levels of NO and IL-17 in the two groups were lower than those before treatment.There was no significant difference between the observation group and the control group(P>0.05)on the 5th day of treatment.The expression levels of NO and IL-17 in the observation group and the control group had statistical significance on the 15th and 30th days of treatment(t=-5.69,-7.87,-24.82,-34.38,P<0.05).There were 57 cases of chemical ulcer and 2 cases of adverse reactions.In the control group,57 cases of peptic ulcer were treated and 2 cases of adverse reactions occurred.There was no significant difference between the two groups(P>0.05).Conclusions:Considering the safety of drug use,the results of the clinical comparative test between the observation group and the control group show that the establishment of the clinical drug treatment program is beneficial to the treatment of patients.Feedback based on clinical efficacy,the clinical effect of Kangfuxin Liquid combined with rabeprazole triple therapy on patients with peptic ulcer is relatively good,which may be correlated with the effect of this therapy on NO and IL-17 in patients with peptic ulcer.